Skip to content
Menu

Nanobiotix S.A. NBTX

Full chart Compare
Set alert

Price alert · NBTX

All alert types
27.32 USD +0.42 (+1.54%)

Regular-session close

27.32 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

27.18 Day range 29.68
19.14 52-week range 57.14
YTD
+18.14%
1 year
+26.11%

 

No chart data for this range yet.
Market cap
1.39B
Revenue (ttm)
11.51M
EPS (ttm)
-1.27
Shares out
50.95M
Forward P/E
-162.85
YTD return
+18.14%
1-year return
+26.11%
50-day average
29.72
200-day average
34.41
Volume
178.00K
Avg volume
147.23K
Open
29.68
Previous close
26.90
Day's range
27.18 – 29.68
52-week range
19.14 – 57.14
Beta
0.54
Price target
53.32 (+95.2%)
Earnings date
Apr 27, 2027

Key statistics

Enterprise value
1.36B
Price / sales
120.95
Revenue growth
-79.20%
Free cash flow
-32.78M
Total cash
110.89M
Total debt
106.61M
Short % of float
0.45%

Fundamental scorecard

6 of 25 checks passed on NBTX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
NBTX Revenue — annual 32.59M
NBTX Net income — annual -23.96M
NBTX EPS — annual -0.50

Earnings

NBTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Apr 27, 2027Dec 30, 20260.05703———
Sep 29, 2026Jun 30, 2026-0.48457-0.7981-0.31-64.70%
Mar 31, 2026Dec 31, 20250.3039-0.45809-0.76-250.74%
Sep 30, 2025Jun 30, 2025-0.24704-0.13367+0.11+45.89%
Apr 2, 2025Dec 31, 2024-0.62-1.01-0.39-63.46%
Nov 12, 2024Jun 30, 2024-0.5117-0.49906+0.01+2.47%

Upgrades / downgrades

NBTX analyst upgrades and downgrades
DateFirmActionFromTo
Jun 4, 2026Leerink PartnersmainOutperformOutperform
May 1, 2026UBSmainNeutralNeutral
Apr 2, 2026GuggenheimmainBuyBuy
Feb 6, 2026GuggenheimmainBuyBuy
Apr 4, 2025GuggenheimmainBuyBuy
Aug 28, 2024Guggenheiminit—Buy

About Nanobiotix S.A.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Sector
Healthcare
Industry
Biotechnology
Country
France

News

Your note

Sign in to keep a note on NBTX — it syncs with the Stock Master app.

Institution ownership

NBTX institution ownership
Holder% heldSharesValueReported
Johnson & Johnson11.03%5,623,816153.61MSep 29, 2026
Citadel Advisors Llc0.70%357,8619.77MSep 29, 2026
Woodline Partners LP0.49%251,4086.87MSep 29, 2026
Jane Street Group, LLC0.06%32,877898.03KSep 29, 2026
HRT Financial LP0.05%26,529724.64KSep 29, 2026
Dorsey Wright & Associates0.03%16,546451.95KSep 29, 2026

Fund ownership

NBTX fund ownership
Holder% heldSharesValueReported
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund0.01%4,489122.62KSep 29, 2026
Steward Funds Inc-Steward Values Enhanced International Fund0.00%1,04828.63KJul 30, 2026
Trust for Professional Managers-ActivePassive International Equity ETF0.00%1,64945.04KAug 30, 2026